证券代码：600285 证券简称：羚锐制药 公告编号：2025-018 号 河南羚锐制药股份有限公司 2024 年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 每股分配比例：每股派发现金红利 0.90 元（含税），不进行资本公积金 转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，公司拟维持每股分配金额不变，相应调整分配总额，并将另行公告具 体调整情况。 本次利润分配方案不触及《上海证券交易所股票上市规则》第 9.8.1 条第 一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 经大华会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司母公司报表中期末未分配利润为人民币 1,947,335,325.69 元。经董事会决议， 公司 2024 年年度拟以实施权益分派股权登记日登记的总股本为基数分配利润， 本次 ...

河南羚锐制药股份有限公司 内部控制审计报告 大华内字[2025]0011000088 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants (Special General Partnership) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn)" 河南羚锐制药股份有限公司 内部控制审计报告 (截止 2024 年 12 月 31 日) 目 页 次 内部控制审计报告 一、、 を食計師事務所 十华会计师事务所 (特殊普通合伙) 舌:86 (10) 5835 0011 传真:86 (10) 内 部 控 制 审 计 报 告 大华内字[2025]0011000088 号 1-2 e 河南羚锐制药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了河南羚锐制药股份有限公司(以下简称羚锐制药) 2024年 12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 ...

河南羚锐制药股份有限公司 审计报告 大华审字[2025]0011007661 号 大华会计师事务所(特殊普通合伙) Da Hua Certified Public Accountants (Special General Partnership) (2024 年 1 月 1 日至 2024 年 12 月 31 日止) | 目 | 求 | 页 次 | | --- | --- | --- | | 审计报告 | | 1-5 | | 已审财务报表 | | | | 合并资产负债表 | | 1-2 | | 合并利润表 | | 3 | | 合并现金流量表 | | র্ব | | 合并股东权益变动表 | | 5-6 | | 母公司资产负债表 | | 7-8 | | 母公司利润表 | | 9 | | 母公司现金流量表 | | 10 | | 母公司股东权益变动表 | | 11-12 | | 财务报表附注 | | 1-97 | 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查理 河南羚锐制药股份有限公司 审计报告及财务报表 二、形成审计意见的基础 我们按照中国注册会计师 ...

非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位： 审计单位： 联系电话： 河南羚锐制药股份有限公司 控股股东及其他关联方资金占用情况的专项说明 (截止 2024年 12月 31 日) 目 录 关于河南羚锐制药股份有限公司 i í 河南羚锐制药股份有限公司 2024 年度非经营 1 性资金占用及其他关联资金往来情况汇总表 第1页 女生会计题事务所 (特殊普通合伙) 由海淀区西四五中路16号码 7号楼 12 层 : 86 (10) 5835 0011 传真: 86 (10) 58 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 专 项 说 明 大华核字[2025]0011003323 号 页 次 | I | 控股股东及其他关联方资金占用情况的专项 1-2 | | --- | --- | | | 说明 | 河南羚锐制药股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了河南羚 锐制药股份有限公司(以下简称羚锐制药)2024年度财务报表,包 括 2024年 12月 31 日的合并及母公司资产负债表,2024年度的 ...

Financial Performance - The company's operating revenue for 2024 reached ¥3,500,831,286.92, representing a year-on-year increase of 5.72% compared to ¥3,311,472,606.54 in 2023[24] - The net profit attributable to shareholders for 2024 was ¥722,550,720.15, a significant increase of 27.19% from ¥568,109,302.85 in the previous year[24] - The basic earnings per share for 2024 was ¥1.287, up 27.17% from ¥1.012 in 2023[26] - The company's total assets as of the end of 2024 amounted to ¥5,016,843,207.73, reflecting a 5.13% increase from ¥4,771,917,373.39 at the end of 2023[25] - The net assets attributable to shareholders increased by 10.09% to ¥3,072,526,287.29 at the end of 2024, compared to ¥2,791,040,844.65 at the end of 2023[25] - The company reported a net cash flow from operating activities of ¥875,864,233.13 for 2024, an increase of 7.68% from ¥813,428,748.87 in 2023[24] - The weighted average return on equity for 2024 was 24.80%, an increase of 3.52 percentage points from 21.28% in 2023[26] Dividend Policy - The company plans to distribute a cash dividend of ¥0.90 per share, totaling approximately ¥510,403,937.40, which accounts for 70.64% of the annual net profit attributable to shareholders[6] - The total number of shares for the cash dividend distribution is 567,115,486, with a cash dividend payout of ¥451,147,133.60 for the fiscal year 2023, based on a total share capital of 567,140,242 shares[159] - Over the last three accounting years, the cumulative cash dividend amount (including tax) reached ¥1,300,007,084.00, with an average annual net profit of ¥585,321,539.03, resulting in a cash dividend ratio of 222.10%[167] - The company has established a three-year shareholder dividend return plan for 2024-2026 to ensure a stable and predictable return mechanism for investors[158] - The company has not proposed a stock dividend or capital reserve transfer to increase share capital for the fiscal year 2024, opting to carry forward the remaining distributable profits to the next year[160] Research and Development - The company has accelerated its digital and intelligent upgrades, enhancing management efficiency through automation technologies[35] - The company is focusing on research and development in major disease areas, including orthopedics and respiratory systems, to strengthen its product line[36] - Research and development expenses increased by 19.95% to 131.53 million RMB, indicating a focus on innovation[68] - The company reported a significant increase in R&D expenditures for projects LR003, LR015, LR002, and LR020, with year-on-year increases of 41.99%, 126.73%, 366.43%, and 362.85% respectively[109] - The company plans to prioritize R&D innovation in traditional Chinese medicine and high-end formulations, particularly in orthopedics and chronic disease management[120] Product Development and Market Strategy - The company completed the construction of production lines for tablets and oral liquid formulations at its Xinyang branch, laying the foundation for future product expansion[35] - The company obtained drug registration certificates for new products, including Montelukast Sodium Chewable Tablets and Metformin Hydrochloride Sustained-Release Tablets[36] - The company signed a letter of intent to acquire controlling interest in Yingu Pharmaceutical Co., Ltd., enhancing its product matrix with high-tech external preparations[37] - The company launched new products such as Tadalafil tablets and Montmorillonite powder, contributing to its growth momentum during the reporting period[39] - The company is focusing on expanding its product lineup in major therapeutic areas such as orthopedics, respiratory, dermatology, and digestive systems[98] Market Presence and Brand Recognition - The company’s pediatric brand "Little Antelope" is being promoted through major media channels, including CCTV and social media, to deepen brand awareness[38] - The company’s "Two Tigers" brand won the Best-Selling Brand Award in the Chinese drug retail market for 2024, indicating strong brand recognition[38] - The company has developed nearly 5,000 hospitals and grassroots medical institutions for its prescription drug business, enhancing its market presence[39] - The company’s unique product, Tongluo Qutong Ointment, is included in the National Essential Drug List and National Medical Insurance Directory, highlighting its market position in orthopedics[61] Operational Efficiency and Management - The company emphasizes a strict supplier management system to ensure the quality and stability of raw material supplies, which is crucial for production[58] - The company follows a "sales-driven production" model, aligning production tasks with market demand and inventory levels to optimize efficiency[59] - The company has a diverse sales model that includes distribution and direct sales, leveraging e-commerce platforms for product promotion[59] - The company is advancing its smart manufacturing capabilities, integrating modern information management systems to enhance production efficiency[65] Risk Management and Compliance - The company does not foresee any significant risks that could materially impact its operations during the reporting period[9] - The company will strengthen its internal control systems to mitigate risks and enhance overall risk management capabilities[119] - The company anticipates potential risks from policy changes in the pharmaceutical industry, emphasizing the need for enhanced management and compliance[126] - The company will implement strict quality management systems to mitigate risks associated with product quality and ensure compliance with national regulations[127] Corporate Governance - The company maintains a robust corporate governance structure, ensuring compliance with relevant laws and regulations while enhancing operational quality[130] - The company’s board of directors operates effectively, with clear responsibilities and adherence to legal requirements, ensuring independent oversight of management activities[132] - The company has established a comprehensive internal control system covering governance, management, finance, human resources, and auditing[133] - The company’s annual financial report received an unqualified opinion, indicating transparency and adherence to disclosure requirements[133] Social Responsibility and Environmental Impact - The company invested 1.1414 million yuan in environmental protection during the reporting period[177] - The company has reported a total donation of 2.1541 million yuan for public welfare projects, including 0.9030 million yuan in cash and 1.2511 million yuan in material donations[185] - The company has implemented measures to reduce carbon emissions, including regular analysis of energy consumption and promoting water conservation[184] - The company has completed the installation and acceptance of video monitoring and online monitoring equipment for wastewater discharge[179]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,020,755,870.55, representing a 12.29% increase compared to CNY 909,046,867.70 in the same period last year[3]. - The net profit attributable to shareholders was CNY 216,817,540.12, up 13.89% from CNY 190,378,639.92 year-on-year[3]. - Basic earnings per share rose to CNY 0.383, a 12.65% increase from CNY 0.340 in the same period last year[3]. - Total operating revenue for Q1 2025 reached ¥1,020,755,870.55, an increase of 12.3% compared to ¥909,046,867.70 in Q1 2024[18]. - Net profit for Q1 2025 was ¥216,733,789.10, representing a 13.9% increase from ¥190,328,634.98 in Q1 2024[19]. - Basic earnings per share for Q1 2025 were ¥0.383, compared to ¥0.340 in Q1 2024, indicating a growth of 12.6%[20]. - The company reported a comprehensive income total of ¥223,044,911.33 for Q1 2025, compared to ¥140,894,063.49 in Q1 2024, reflecting a significant increase of 58.3%[20]. Cash Flow - The net cash flow from operating activities increased significantly by 161.91%, reaching CNY 117,615,900.12, compared to CNY 44,906,293.79 in the previous year[3]. - Cash received from sales of goods and services in Q1 2025 was ¥895,511,232.10, an increase from ¥761,878,217.97 in Q1 2024, marking a growth of 17.5%[22]. - Operating cash inflow totaled $903,232,099.55, an increase from $809,623,301.08 in the previous period[23]. - Net cash flow from operating activities reached $117,615,900.12, significantly up from $44,906,293.79[23]. - The ending cash and cash equivalents balance was $570,929,618.67, down from $1,466,278,009.71[24]. - The company experienced a net decrease in cash and cash equivalents of $657,448,187.33 during the period[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,410,895,780.92, reflecting a 7.85% increase from CNY 5,016,843,207.73 at the end of the previous year[4]. - Total liabilities rose to ¥2,067,027,296.35, compared to ¥1,936,551,143.73 in the previous period, reflecting an increase of 6.8%[14]. - The total equity attributable to shareholders was CNY 3,311,522,505.91, which is a 7.78% increase from CNY 3,072,526,287.29[4]. - Shareholders' equity increased to ¥3,343,868,484.57, up from ¥3,080,292,064.00, indicating a growth of 8.6%[15]. Investments and Acquisitions - The company approved the acquisition of 90% equity in Yingu Pharmaceutical Co., Ltd. for RMB 703,908,000, which was completed in March 2025[10]. - The company's intangible assets increased significantly from RMB 203,746,216.32 to RMB 317,123,551.29, marking an increase of approximately 55.5%[13]. - The goodwill recorded as of March 31, 2025, was RMB 482,016,236.04, indicating the company's strategic investments in acquisitions[13]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,288[8]. - The largest shareholder, Henan Lingrui Group Co., Ltd., holds 121,817,898 shares, accounting for 21.48% of the total shares, with 26,930,000 shares pledged[8]. - The company has not reported any changes in the top 10 shareholders or their participation in margin financing and securities lending activities[10]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥780,335,122.23, up from ¥696,497,752.04 in Q1 2024, reflecting a growth of 12.0%[18]. - Research and development expenses for Q1 2025 were ¥22,799,572.17, compared to ¥20,393,113.38 in Q1 2024, showing an increase of 11.8%[19].

2024 年度独立董事述职报告 (李慧) 作为河南羚锐制药股份有限公司(以下简称"公司")的独立董事,2024_年, 本人按照《公司法》《上市公司独立董事管理办法》《上海证券交易所上市公司自 律监管指引第 1 号 -- 规范运作》等法律法规、规范性文件以及《公司章程》、 《独立董事工作制度》等规定,勤勉尽责地履行独立董事职责,审慎行使公司和 股东所赋予的权利,出席了公司相关会议,认真审议董事会各项议案,充分发挥 独立董事作用,对董事会的科学决策、规范运作起到了积极作用,切实维护全体 股东尤其是中小股东的合法权益。现将本人 2024年度履职情况报告如下: 一、独立董事的基本情况 (一)个人履历 李慧,女,汉族,1967年7月生,博士。现任中国中医科学院首席研究员、 河南羚锐制药股份有限公司独立董事。 (二)是否存在影响独立性的情况说明 河南羚锐制药股份有限公司 作为公司的独立董事,本人具有履行独立董事职责所必需的专业能力和工作 经验,具备《上市公司独立董事管理办法》等法律法规所要求的独立性,并在履 职中保持客观、独立的专业判断,不存在影响独立性的情况。 二、独立董事年度履职概况 (一) 2024年度出席会议情况 ...

2024年 (杨 ) (以 " ")的 ,2024年 , 1号—— ,勤 ,审 ,出 ,认 ,充 ,对 ,切 2024年 : (一 )独 ,男 ,汉 ,1969年 12月 ,工 ,中 ,2023年 5月 (二 )是 ,本 ,具 ,并 ,不 (一 )2024年 1、 2024年 ,公 8次 2次 ,本 ,亲 ,积 ,本 ,充 ,会 ,与 ,积 ,利 ,对 ,没 ,2024年 ,重 2、 2024年 ,公 1次 1次 5次 5次 ,本 ,积 ,并 ,就 ,以 ,为 3、 2024年 ,公 1次 ,本 ,就 2024 2025年 ,本 ,切 (二 )现 2024年 ,本 ,充 ,并 ,与 ,及 ,积 , ,为 ,主 :在 ,相 ,充 ,为 (三)与 ,本 ,督 ;与 ,充 ,履 , ,切 (一 )关 2024年 11月 29日 ,公 2024 2025年 ,本 ,经 ,本 ,关 ,定 ,不 ,也 ;在 ,关 ,符 (二 )披 ,本 , ,符 ;公 ,内 ,符 (三 )聘 (四 )与 ,本 ,与 ,密 ,督 , ,提 ,不 ,切 ,经 ,董 ,公 (特 )为 2024年 , ,公 (四 )会 , ,能 ,不 ,不 ( ...

根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，公司董事会就 公司独立董事李慧、杨钧、张钦昱 2024 年度独立性情况进行评估并出具如下专 项意见: 经核查公司独立董事李慧、杨钧、张钦昱的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立董事 独立性的相关要求。 河南羚锐制药股份有限公司董事会 河南羚锐制药股份有限公司 二○二五年四月二十四日 董事会对独立董事 2024 年度独立性情况评估的专项意见 ...

河南羚锐制药股份有限公司 2024 年度独立董事述职报告 (张敏昱) 作为河南羚锐制药股份有限公司(以下简称"公司")的独立董事,2024年, 本人按照《公司法》《上市公司独立董事管理办法》《上海证券交易所上市公司自 律监管指引第 1 号 -- 规范运作》等法律法规、规范性文件以及《公司章程》、 《独立董事工作制度》等规定,勤勉尽责地履行独立董事职责,审慎行使公司和 股东所赋予的权利,出席了公司相关会议,认真审议董事会各项议案,充分发挥 独立董事作用,对董事会的科学决策、规范运作起到了积极作用,切实维护全体 股东尤其是中小股东的合法权益。现将本人 2024年度履职情况报告如下: 一、 独立董事基本情况 报告期内,因独立董事梅夏英先生申请辞去独立董事职务,经公司第九届董 事会第七次会议及 2023年年度股东大会审议通过,补选本人为公司独立董事。 张钦昱,男,汉族,1985年5月生,法学博士。现任中国政法大学经济法 研究所所长,河南羚锐制药股份有限公司独立董事。 (二)是否存在影响独立性的情况说明 作为公司的独立董事,本人具有履行独立董事职责所必需的专业能力和工作 经验,具备《上市公司独立董事管理办法》等法律法规 ...